Nephros (NEPH) vs InspireMD (NSPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nephros (NEPH) has outperformed InspireMD (NSPR) over the past year, losing 46.4% versus a loss of 72.0%. Over five years, NEPH leads with a -63.6% price change compared with -85.1% for NSPR. InspireMD is the larger company by market cap ($29.2 million vs $28.4 million), about 1.0 times the size, while Nephros is growing revenue faster (+32.7% vs +28.1%).
Nephros converts more of its revenue into profit, with a net margin of 6.4% versus -543.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NEPH | NSPR |
|---|---|---|
| Share price | $2.61 | $0.54 |
| Market cap | $28.37M | $29.23M |
| 1-day change | -8.10% | -12.97% |
| YTD return | -46.52% | -69.66% |
| 1-year return | -46.41% | -72.02% |
| 5-year return | -63.60% | -85.12% |
| P/E ratio (TTM) | 15.35 | — |
| Forward P/E | 11.86 | — |
| EPS (TTM) | $0.17 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $18.79M | $8.98M |
| Revenue growth (YoY) | +32.67% | +28.11% |
| Net income (latest FY) | $1.19M | $-48.79M |
| Gross margin | 61.87% | 29.50% |
| Operating margin | 6.10% | -552.56% |
| Net margin | 6.35% | -543.33% |
| 52-week high | $6.42 | $2.17 |
| 52-week low | $2.61 | $0.43 |
| Distance from 52-week high | -59.35% | -75.12% |
| Analyst consensus | none | none |
| Avg. price target upside | +139.46% | +516.67% |
| Average volume | 48.33K | 234.68K |
| Shares outstanding | 10.87M | 54.13M |
| Employees | 36 | 127 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NEPH has outperformed NSPR by 25.6 percentage points over the past year.
- Nephros is more profitable, keeping 6.4 cents of every revenue dollar as net income versus -543.3 cents for InspireMD.
About Nephros
NEPH stock →Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities.
Health Care · Medical/Dental Instruments · 36 employees
About InspireMD
NSPR stock →InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions.
Health Care · Medical/Dental Instruments · 127 employees
NEPH vs NSPR FAQ
Which is bigger, Nephros or InspireMD?
InspireMD (NSPR) is larger, with a market capitalization of $29.23M compared with $28.37M for Nephros (NEPH).
Which stock has performed better over the past year, NEPH or NSPR?
NEPH returned -46.41% over the past 12 months, compared with -72.02% for NSPR (price return, excluding dividends). Past performance does not predict future results.
Are Nephros and InspireMD in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.